TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor

Sabine Klein¹, Carola-Ellen Kleine², Andrea Pieper³, Michaela Granzow², Sebastian Gautsch², Mimoun Himmit², Katharina Kahrmann², Robert Schierwagen¹, Frank Erhard Uschner¹, Fernando Magdaleno², Maria Eleni Naoum¹,³, Glen Kristiansen⁴, Thomas Walther⁵,⁶, Michael Bader⁷,⁸,⁹,¹⁰,¹¹, Tilman Sauerbruch² & Jonel Trebicka¹,¹²,¹³,¹⁴

Prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing. Resulting fibrosis and portal hypertension, as a possible secondary event, may necessitate treatment. Overexpression of mouse renin in the transgenic rat model, TGR(mREN2)27, leads to spontaneous development of NAFLD. Therefore, we used TGR(mREN2)27 rats as a model of NAFLD where we hypothesized increased susceptibility and investigated fibrosis and portal hypertension and associated pathways. 12-week old TGR(mREN2)27 rats received either cholestatic (BDL) or toxic injury (CCl₄ inhalation). Portal and systemic hemodynamic assessments were performed using microsphere technique with and without injection of the Janus-Kinase 2 (JAK2) inhibitor AG490 or the non-peptidic Ang(1-7) agonist, AVE0991. The extent of liver fibrosis was assessed in TGR(mREN2)27 and wild-type rats using standard techniques. Protein and mRNA levels of profibrotic, renin-angiotensin system components were assessed in liver and primary hepatic stellate cells (HSC) and hepatocytes. TGR(mREN2)27 rats developed spontaneous, but mild fibrosis and portal hypertension due to the activation of the JAK2/Arhgef1/ROCK pathway. AG490 decreased migration of HSC and portal pressure in isolated liver perfusions and in vivo. Fibrosis or portal hypertension after cholestatic (BDL) or toxic injury (CCl₄) was not aggravated in TGR(mREN2)27 rats, probably due to decreased mouse renin expression in hepatocytes. Interestingly, portal hypertension was even blunted in TGR(mREN2)27 rats (with or without additional injury) by AVE0991. TGR(mREN2)27 rats are a suitable model of spontaneous liver fibrosis and portal hypertension but not with increased susceptibility to liver damage. After additional injury, the animals can be used to evaluate novel therapeutic strategies targeting Mas.

Due to lifestyle changes, prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide¹. Only a small percent of the NAFLD patients, especially those with hepatic steatosis, will develop more severe forms...
of hepatic disease (fibrosis, cirrhosis). Therefore, steatosis, fibrosis and the development of portal hypertension are the principal parameters that indicate the necessity for treatment. NAFLD is induced by various mechanisms, some of which may be modulated by drugs. However, substances acting directly on fibrogenesis and portal hypertension are rare. Thus, blunting the activation of hepatic stellate cells in TGR(mREN2)27 rats represents an appropriate target. Fibrosis and deposition of extracellular matrix (ECM) increases portal blood outflow resistance. In addition, activated HSC are hyperresponsive to vasoconstrictors (e.g. angiotensin II), which further augments hepatic resistance to portal flow. Finally, as development of portal hypertension is associated with morbidity and mortality, adequate therapies are important. In view of the above-mentioned demographic changes, new animal models are necessary for preclinical drug testing.

TGR(mREN2)27 is such a model, comprising the overexpression of mouse renin in transgenic rats, which leads to spontaneous development of NAFLD, and underlining the pathogenic role of the renin-angiotensin system (RAS) in liver disease. The role of RAS in portal hypertension is ambiguous. There exist two main axes within RAS: the classic pathway with angiotensin-converting enzyme (ACE), angiotensin (Ang) II, Ang II-type-1 receptor (AT1R) mediating vasoconstriction - and the alternative pathway, whereby ACE2, Ang1-7, and the G-protein-coupled receptor Mas (MasR) mediate relaxation. Ang II, the agonist of the pro-fibrotic and pro-contractile AT1R, exerts its effects through Janus-Kinase 2 (JAK2) in HSC. In the alternative RAS, ACE2 converts Ang II to Ang-(1-7), the agonist for MasR, inducing vasorelaxation mainly through nitric oxide synthase. The alternative RAS has been also shown to exert beneficial effects in cirrhosis. Interestingly, renin sets off the cascade for both, the classic and the alternative RAS, by mediating the generation of Ang I from angiotensinogen, which is further converted to Ang II by ACE, and can be further converted to Ang-(1-7) through the enzymatic activity of ACE2. Inhibition of renin, which is upstream of both pathways, leads to improved liver fibrosis and portal hypertension, suggesting a preponderance of the classic AT1R mediated pathway. However, in humans, the renin concentration can be significantly increased by treatment with AT1R-blockers, but is absent in most animal models we used TGR(mREN2)27 rats as a model of renin-induced NAFLD. After inducing additional liver injury (BDL, CCl4) in TGR(mREN2)27 rats, we investigated whether these animals are more prone to fibrosis and portal hypertension.

Results

TGR(mREN2)27 rats develop spontaneous fibrosis and portal hypertension, but are not more prone to cholestatic or toxic liver damage. The extent of fibrosis was assessed in TGR(mREN2)27 and wild type (WT) rats, uninjured or subjected to BDL and CCl4 (Fig. 1). Healthy uninjured TGR(mREN2)27 rats show more positive hepatic Sirius red staining compared to respective WT rats. There was no significant difference among the extent of fibrosis in Sirius red staining in WT and TGR(mREN2)27 rats after injury (Fig. 1A, Suppl. Fig. 1A). Interestingly, in uninjured TGR(mREN2)27 rats, periportal fibrosis was observed when compared to WT rats (Fig. 1A). Levels of hydroxyproline were significantly higher in TGR(mREN2)27 rats than in WT rats without injury (Fig. 1B). Control TGR(mREN2)27 and WT animals showed similar collagen I A I (Col1a1) mRNA levels. While there was only a trend towards decreased collagen synthesis in TGR(mREN2)27 rat livers two weeks after BDL, the difference to wildtype rats became significant after four weeks of BDL. Congruent to this finding, ten weeks of CCI4 intoxication, TGR(mREN2)27 rats showed less hepatic Col1a1 mRNA expression than the respective WT rats (Fig. 1C). While healthy TGR(mREN2)27 rats had more positive alpha smooth muscle actin (αSMA) areas, marker of activation of hepatic stellate cells, in livers compared to respective WT livers, the hepatic αSMA increased much less after CCI4 intoxication in TGR(mREN2)27 intoxicated WT livers (Fig. 1D, Suppl. Fig. 1B). This was also confirmed by the total protein levels of αSMA (Suppl. Fig. 1C), but mRNA levels showed no differences between WT and TGR(mREN2)27 livers at baseline and after pathological stimuli (Fig. 1E). Already two weeks after BDL, hepatic platelet derived growth factor (PDGF)-beta receptor transcription showed a trend towards lower mRNA levels in TGR(mREN2)27 rat livers, reaching significance four weeks after BDL and in the CCI4 model (Fig. 1F).

TGR(mREN2)27 rats showed spontaneous portal hypertension, due to increased portal pressure and hepatic vascular resistance (Table 1). However, after four weeks of BDL injury, the degree of portal hypertension in TGR(mREN2)27 rats was similar to that found in WT rats, while CCI4-injury produced even less portal hypertension in TGR(mREN2)27 rats due to decreased hepatic vascular resistance compared to WT rats (Table 1). While mean arterial pressure (MAP) was higher in CCI4 intoxicated TGR(mREN2)27 rats compared to WT rats, systemic vascular resistances were not significantly different (Table 1).

Expression of RAS components in TGR(mREN2)27 rats. Interestingly, hepatic angiotensinogen mRNA levels decreased after BDL, which was more pronounced in TGR(mREN2)27 rats (Fig. 2A). ACE and ACE2 mRNA increased after liver injury, but to a lesser extent in TGR(mREN2)27 rat livers than in WT livers (Fig. 2B,C). Moreover, hepatic rat renin mRNA expression was down-regulated after liver injury, with down-regulation most pronounced in TGR(mREN2)27 rats after four weeks of BDL. This direction of regulation was opposed in CCI4 TGR(mREN2)27 rat livers compared to the respective WT livers (Fig. 2D). In contrast, expression of hepatic transgene (mouse renin) was down-regulated in TGR(mREN2)27 rats (Fig. 2E), which was most likely due to the down-regulation in the hepatocytes, as shown in primary isolated hepatocytes from BDL TGR(mREN2)27 rats compared to control TGR(mREN2)27 rats (Fig. 2F).

AT1R-dependent pathways in TGR(mREN2)27 rats. Since TGR(mREN2)27 rats showed no major differences compared to WT rats in the in vivo disease models, we next analyzed HSC as the major cellular...
A contributor of liver fibrosis. Compared to WT HSC, HSC isolated from TGR(mREN2)27 showed higher aSMA mRNA expression without changes in collagen mRNA (Fig. 3A).

To evaluate the motility of the cells, we investigated migration using the scratch assay, in which HSC isolated from TGR(mREN2)27 showed higher migration capacity than WT HSC (Fig. 3B).

**Table 1.** Hemodynamics in healthy and fibrotic TGR(mREN2)27 rats. */**/***p < 0.05/p < 0.005/p < 0.0001 vs. respective WT.
Interestingly, the mRNA levels of ACE, AT2R and Mas suggest an elevated cellular alternative RAS pathway in activated HSC of TGR(mREN2)27 rats gained from livers of uninjured TGR(mREN2)27 rats (Fig. 3C). Although most downstream pathways activated by AT1R were similarly regulated in WT and TGR(mREN2)27 HSC, congruent to the unaltered mRNA expression of the receptor, HSC from TGR(mREN2)27 HSC showed significantly elevated ROCK2 expression (Fig. 3D). Interestingly, the total hepatic AT1R protein expression was elevated, but only on basal condition TGR(mREN2)27 rats and this difference disappeared after additional liver injury (Fig. 3E, Suppl. Fig. 1D). In parallel to this finding, JAK2 phosphorylation and its downstream component Arhgef1 were overexpressed in the control TGR(mREN2)27 rat livers when compared to WT (Fig. 3F, Suppl. Fig. 1C), a difference that could not be observed under liver injury conditions.

In order to test whether this up-regulation is relevant for the spontaneous portal hypertension observed in TGR(mREN2)27 rats (Table 1), AG490 compound was used to inhibit JAK2. Indeed, AG490 decreased portal pressure and hepatic vascular resistance in TGR(mREN2)27 rats (Fig. 4A). This effect was also confirmed by in situ liver perfusion experiments in TGR(mREN2)27 livers, showing a dose-dependent relaxation of the intrahepatic vascular system (Fig. 4B). Furthermore, migration of TGR(mREN2)27 HSC was blunted by AG490 (Fig. 4C).

**Role of Mas in TGR(mREN2)27 rats.** Interestingly, hepatic Mas expression tended to be higher in TGR(mREN2)27 rats than in WT rats at mRNA and protein levels, reaching significance in CCl4 induced fibrosis (Fig. 5A,B, Suppl. Fig. 1D). To test whether this up-regulation of Mas is relevant in vivo, its agonist AVE0991 was injected in control TGR(mREN2)27 animals, as well as after four weeks of BDL and ten weeks of CCl4. A significant decrease of portal pressure due to a drop in hepatic vascular resistance was observed in TGR(mREN2)27 rats in all models (Fig. 5C,D, Table 2). Secondary changes in the systemic circulation were also observed. However, in splanchnic vascular resistance, they were not significant (Table 2).

Interestingly, AVE0991 decreased Mas expression but led to a relative increase in ACE2 mRNA levels (Fig. 5E,F), which might be a feedback regulation to the reduced Mas mRNA expression in response to AVE0991. Notably, ACE and AT1R were not substantially influenced (Suppl. Fig. 1E,F).

**Discussion**

This study shows for the first time that TGR(mREN2)27 rats develop spontaneous fibrosis and portal hypertension, in addition to previously described steatosis and inflammation[5]. Renin-induced portal hypertension can be ameliorated either by JAK2 inhibitors or Mas agonists. Surprisingly, renin overexpression does not exacerbate cholestatic or toxic liver damage.
Modulation of RAS might play an important role in the treatment of human NAFLD\textsuperscript{27,28}, suggesting a pathogenic involvement of RAS in the development and progression of NAFLD. NAFLD is an emerging etiology of liver disease and almost 30% of the patients suffer from portal hypertension, which is associated with fibrosis in almost 90% of the patients\textsuperscript{3}. The TGR(mREN2)\textsuperscript{27} rat model has been described to exhibit pronounced steatosis and inflammation already at an age of 12 weeks\textsuperscript{12} and the present study demonstrates that these animals also develop fibrosis and portal hypertension. This further confirms TGR(mREN2)\textsuperscript{27} as a suitable model to investigate renin-induced liver injury and portal hypertension. Moreover, TGR(mREN2)\textsuperscript{27} rats represent a NAFLD model of rats with mild fibrosis and significant portal hypertension regardless of any specific diet. To date, all NAFLD rat models necessitate an extended diet treatment and, while the animals might develop portal hypertension, they nevertheless fail to develop inflammation or fibrosis\textsuperscript{29–31}. Thus, the TGR(mREN2)\textsuperscript{27} rat model possibly offers an advantage over the diet models in wild type rats\textsuperscript{29–31}.

The concept that co-factors of liver injury may maintain portal hypertension has already been adopted by the Baveno VI guidelines\textsuperscript{32}, and was tested in TGR(mREN2)\textsuperscript{27} rats. However, this concept could not be implemented in the rats in our study, since the mouse renin expression - responsible for the development of liver fibrosis and portal hypertension - was reduced upon cholestatic or toxic liver injury. This reduction was probably caused by the injury inducing loss of hepatocytes, which are the majority cell type in the liver. During liver injury the number of hepatocytes diminishes, and as shown by our study the gene expression of mREN is decreased in the hepatocytes from fibrotic animals. This reduced mouse renin expression due to injury might explain the lacking difference between WT and TGR(mREN2)\textsuperscript{27} rats after liver injury.

However, the TGR(mREN2)\textsuperscript{27} rats without an additional liver injury are an interesting model of liver disease since these animals develop NAFLD with fibrosis and portal hypertension. Indeed, classic and alternative RAS play an important role in different models of experimental liver cirrhosis and in different etiologies of human liver cirrhosis\textsuperscript{8,14–16}. TGR(mREN2)\textsuperscript{27} rats exhibit these properties, which confirms their suitability as a model of liver disease. One of the pathways mediating portal hypertension in TGR(mREN2)\textsuperscript{27} rats is the overactivation of the JAK2-dependent pathway downstream of AT1R. Several lines of evidence confirmed this conclusion. First, the

![Figure 3](https://www.nature.com/scientificreports/)
transcription levels of the main components of the pathway including AT1R were increased. Further, activation and protein expression of JAK2 and Arhgef-1, and, finally, inhibition of JAK2 using AG490 decreased hepatic resistance and thereby portal pressure in these animals. Previously, we demonstrated that downstream of AT1R, JAK2/Arhgef1 is activated and mediated through ROCK fibrosis and portal hypertension\(^8,9\). These findings were independently confirmed by others\(^{33}\). In uninjured TGR(mREN2)27 rats, JAK2 inhibition mediated relaxation of hepatic stellate cells, slowed their migration and thereby decreased portal pressure \(\text{in vivo}\) via a decrease in hepatic vascular resistance, which was shown \(\text{in vivo}\) and in isolated liver perfusions.

Similar to human liver cirrhosis with portal hypertension, TGR(mREN2)27 rats showed elevated Mas expression\(^{15}\). AVE0991, the non-peptidic agonist of Mas, could blunt portal hypertension due to massive hepatic vasodilation in TGR(mREN2)27 rats, in either uninjured or cirrhotic (BDL, CCl\(_4\)) models. Again, this indicates that Mas is an important effector of the vasculature in the presence of portal hypertension as described previously by others\(^{13}\). In uninjured TGR(mREN2)27 rats, JAK2 inhibition mediated relaxation of hepatic stellate cells, slowed their migration and thereby decreased portal pressure \(\text{in vivo}\) via a decrease in hepatic vascular resistance, which was shown \(\text{in vivo}\) and in isolated liver perfusions.

In summary, TGR(mREN2)27 rats develop spontaneous liver fibrosis and portal hypertension and are a suitable NAFLD model with mild liver fibrosis and portal hypertension. In particular after toxic or cholestatic liver injury, may TGR(mREN2)27 rats be used to develop novel therapeutic strategies targeting Mas.

**Figure 4.** Jak2 upregulation in TGR(mREN2)27 rats. (A) Portal pressure and hepatic-vascular resistance before and after injection of 1 mg/kg AG490. In TGR(mREN2)27 rats, portal pressure was significantly reduced after inhibition of Jak2 by AG490. Unit of portal pressure measurement is mmHg and of hepatic-vascular resistance mmHg*min*100 g/ml. (B) Perfusion pressure \(\text{in situ}\) in livers of TGR(mREN2)27 rats after precontraction with 5 µM Ang II and after 10\(^{-6}\) and 10\(^{-5}\)M AG490 in the perfusion buffer. Results are represented as percentage of the basal perfusion pressure. (C) Scratch assay of TGR(mREN2)27 HSC with and without AG490 treatment (5 µM and 25 µM) after 24 h. Migration of TGR(mREN2)27 HSC is represented as percentage of gap. Gap of untreated HSC are normalized to 100%. Error bars are means ± s.e.m. Statistical analyzes; Paired Wilcoxon signed rank test. \(^\wedge/\wedge\wedge\)Indicates \(p < 0.05/p < 0.005\) compared to measurement before AG490 treatment. \(^\wedge/\wedge\wedge\wedge\)Indicates \(p < 0.05/p < 0.0001\) compared to TGR(mREN2)27 control data.
Figure 5. Overexpression of Mas in TGR(mREN2)27 rats. (A) Hepatic Mas mRNA expression in WT and TGR(mREN2)27 rats without liver injury (control) and after injury (BDL 2w, BDL 4w, CCl4 10w). mRNA expression data were normalized to WT control data and illustrated as x-fold change. (B) Quantification of hepatic Mas protein expression. Hepatic protein expression of Mas in TGR(mREN2)27 livers (control, BDL 2w, BDL 4w, CCl4 10w) compared and normalized to WT Mas protein expression data. Results are shown as percentage of densitometric units and WT data were set at 100% and illustrated as a line. (C) Portal pressure in TGR(mREN2)27 rats. Portal pressure was measured in mmHg before and after AVE injection in control, BDL and CCl4 intoxicated TGR(mREN2)27 rats. (D) Hepatic-vascular resistance in TGR(mREN2)27 rats. Hepatic-vascular resistance was measured in control, BDL and CCl4 intoxicated TGR(mREN2)27 rats before and after AVE injection. Results are shown as mmHg*min*100 g/ml. (E) Hepatic Mas mRNA expression with and without AVE injection in TGR(mREN2)27 rats. Hepatic Mas mRNA was measured in control, BDL and CCl4 injected TGR(mREN2)27 rats without and with AVE injection. Data were normalized to control mRNA data without AVE treatment and represented as x-fold change. (F) Hepatic ACE2 mRNA expression with and without AVE injection in TGR(mREN2)27 rats. ACE2 mRNA expression was measured in livers of control, BDL and CCl4 intoxicated TGR(mREN2)27 rats with and without AVE injection. All data were normalized to control data without AVE injection and shown as x-fold change. Error bars are means ± s.e.m. Statistical analyzes; Mann-Whitney t-test. */**/*** Indicates p < 0.05/p < 0.005/p < 0.0001 vs. before AVE injection.

Table 2. Hemodynamics in healthy and fibrotic TGR(mREN2)27 rats before and after AVE0991 injection. */**/*** p < 0.05/p < 0.005/p < 0.0001 vs. before AVE0991 injection.
Materials and Methods

Animals and models of liver disease.  Animals.  We used 79 Sprague-Dawley wild type (WT) and 90 TGR(mREN2)27 rats. Experimental procedures were approved by the Animal Ethics Committee of Austin Health and of North Rhine-Westphalia (LANUV 84-02.04.2014.A137). WT and TGR(mREN2)27 rats were housed in a controlled environment (12 hour light/dark, temperature 22 °C to 24 °C) and fed standard rat chow ad libitum (Norco, Lismore NSW, Australia; Sniff, Soest, Germany) with free access to water.

Toxic model.  Eight WT and 20 TGR(mREN2)27 rats (100 g) underwent twice weekly inhalation of 1/11m CCl₄ for ten weeks until ascites was present as described previously⁹,34. Age-matched control rats (ten WT and ten TGR(mREN2)27) did not receive CCl₄.

Cholestatic model. After one week of acclimatization, BDL was performed as previously described in 40 WT and 45 TGR(mREN2)27 rats (180 g) for four weeks⁹,34. BDL rats were compared to 21 WT and 15 TGR(mREN2)27 sham-operated rats.

Hemodynamic studies.  In-vivo hemodynamic studies.  Once rats had developed ascsises as a definite sign for the presence of portal hypertension, the animals were used for hemodynamic studies as described previously⁹,34. To assess the acute effect of AVE0991 or AG490, invasive measurements of mean arterial pressure (MAP) and portal pressure (PP) were performed in cirrhotic rats. AVE0991 or AG490 was administered at a dose of 1 mg/kg in the femoral vein.

Microsphere technique. To investigate hemodynamics, the colored microsphere technique was performed as described previously⁹,34. Before and 1 h after injection of AVE0991 or AG490, 300.000 systemic (red/white) microspheres (15 µm diameter, Triton-Technologies, San Diego, USA) were injected in the left ventricle. Mesenteric portosystemic shunt volume was estimated before and after injection of 150.000 microspheres (yellow/blue) in the ileocecal vein.

In situ liver perfusion. In ten cirrhotic CCl₄ intoxicated TGR(mREN2)27 rats, in situ liver perfusion was performed in a recirculating system as described previously⁹,34. After a stabilization period of 30 minutes, pre-contraction of the liver was induced by adding 5µM Ang II to the Krebs-Henseleit solution. Thereafter, AG490 was added to the Krebs-Henseleit solution (10⁻⁶ and 10⁻⁷ M).

Hepatic hydroxyproline content. The hepatic hydroxyproline content was determined photometrically in analogue segments (200 mg) of snap-frozen livers as described previously⁸,35.

Tissue collection. Healthy control rats and animals after induction of liver fibrosis were anesthetized and laparotomy was performed for tissue collection. The livers were cut into fragments and stored at −80 °C until they were used for qRT-PCR and Western blot analysis as described previously⁸,35. Segments of each liver were fixed in formaldehyde (4%) for paraffin embedding as described previously⁸,35.

Histological staining. Paraffin-embedded liver sections (2–3 µm) were treated with 0.1% Sirius red in saturated picric acid (Chroma, Münster, Germany) to detect collagen fibers. Hepatic Sirius red stainings were digitalized using Pannoramic MIDI (3DHistech, Budapest, Hungary) and quantified using Histoquant (3DHistech, Budapest, Hungary) as previously described⁸,35.

Isolation of primary hepatocytes and hepatic stellate cells. Primary rat hepatic stellate cells were isolated and cultured as previously described⁸,35. Viability and purity were routinely >95%. For early activation of HSCs, cells were harvested on day 10.

Cell culture. Rat hepatic stellate cells were incubated in cell culture medium (DMEM + 20% FBS + penicillin/streptomycin) in 250 ml plastic flasks at 37 °C. After reaching 80% confluence, cells were passaged with a 1:3 split ratio. Detachment was achieved by incubating the cells with 0.05% Trypsin/EDTA solution (solved in PBS) for five minutes at 37 °C. Confluent hepatic stellate cells were incubated in media with 5µM AG490 or with 10⁻⁵ M AVE0991 and harvested three days later for qRT-PCR.

Wound healing assay.Cells were cultured in cell culture medium (DMEM + 20% FBS + penicillin/streptomycin) in 24-well plastic dishes at 37° Celsius. When cells were confluent the cell culture medium was withdrawn by suction and changed with the respective media. A scratch was made with a size of 1 mm. After one, two, and three days, the diameter of the scratch was measured and quantified using a Zeiss microscope (Primo Star, SF18). The results are shown as the percentage of the gap size.

qRT-PCR. Hepatic stellate cells and liver homogenates from either fibrotic or non-fibrotic rats were prepared using previously described methods⁸,35. RNA isolation, reverse transcription, and detection by real-time polymerase chain reaction (RT-PCR) were performed as described previously⁸,35. RNA was isolated from samples using the Qiazol reagent as instructed by the manufacturer (Qiagen, Hilden, Germany). The following assays provided by Applied Biosystems (Foster City, USA) were used: ACTA2 (Rn01416293_m1), COL1A1 (Rn00801649_m1), Tgfb1 (Rn00572010_m1), PDGFB (Rn00709573_m1), Angiotensinogen (Rn00593114_m1), ACE (Rn00561904_m1), ACE2 (Rn0146293_m1), AT1R (Rn01435427_m1), Mas (Rn00562673_s1), Ccl2 (Rn00580535_m1), Emr1 (Rn01527631_m1), Renin rat (Rn00561847_m1), Renin mouse (Mm00651435_mH),
Western blotting. Hepatic stellate cells and liver samples were processed as previously described using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and nitr cellulose membranes. Equal protein loading was assured using Ponceau-S staining. GAPDH served as endogenous control of protein expression. Membranes were incubated with rabbit anti- Arhgef1 (Rn0067341_m1), RhoA (Rn04219609_m1) and Rock2 (Rn00564633_m1) (was provided by Qiagen (Hilden, Germany)). Samples were normalized to 18s rRNA.

Statistical analysis. Group size was at least n = 5 for each group. Graphs are presented as means ± standard error of the mean (SEM) and p-values < 0.05 were considered statistically significant. Western blots were measured using digital densitometry software (Bio-1D v.15.02, Vilber Lourmat, Marne-la-Vallée, France) and the respective density of each band was calculated. The fibrosis groups were tested for significance to their corresponding controls using Mann-Whitney U test. In qPCR experiments, 2^{−ΔΔCT} was calculated and normalized to the respective control group. Plotting of diagrams and statistical analysis were performed using GraphPad Prism version 4.00 for Windows (GraphPad Software, La Jolla, California, USA).

All methods were performed in accordance with the relevant guidelines and regulations.

References
1. Rasouli, N., Bellantoni, S., Cortez-Pinto, H., Day, C. & Marchesini, G. A position statement on NASH/NASH based on the EASL 2009 special conference. Journal of hepatology 53, 372–384 (2010).
2. Mendes, F. D., Suzuki, A., Sanderson, S. O., Lindor, K. D. & Angulo, P. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. *Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association* 10, 1028–1033 e1022 (2012).
3. Nagpal, S. J. et al. Portal Hypertension Complications Are Frequently the First Presentation of NASH in Patients Undergoing Liver Transplantation Evaluation. *Digestive Diseases and sciences* 61, 2102–2107 (2016).
4. Rotman, Y. & Sanyal, A. J. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. *Gut* 66, 180–190 (2017).
5. Maderacke, I. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. *Nature communications* 4, 2823, https://doi.org/10.1038/ncomms3823 (2013).
6. Friedman, S. L. Mechanisms of hepatic fibrogenesis. *Gastroenterology* 134, 1655–1669 (2008).
7. Bosch, J. & Garcia-Pagan, J. C. Complications of cirrhosis. I. Portal hypertension. *Journal of hepatology* 32, 141–156 (2000).
8. Granzow, M. et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. *Hepatology* 60, 334–348 (2014).
9. Klein, S. et al. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. *Gut* 66, 145–155 (2017).
10. Benvegnu, L., Gios, M., Boccatto, S. & Alberti, A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. *Gut* 53, 744–749 (2004).
11. Sauerbruch, T. & Treibicka, J. Future therapy of portal hypertension in liver cirrhosis - a guess. F1000prime reports 6, 95 (2014).
12. Wei, Y. et al. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic Tg(mRen227/2Ren2) rats. *Journal of hepatology* 49, 417–428 (2008).
13. Santos, R. A. S. et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). *Physiol Rev* 98, 505–553 (2018).
14. Lubel, J. S. et al. Angiotensin-(1-7), an alternative metabolite of the renin–angiotensin system, is up-regulated in human liver disease and has anti-fibrotic activity in the bile-duct-ligated rat. *Clinical science* 117, 375–386 (2009).
15. Grace, J. A. et al. Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilation in cirrhosis. *Gastroenterology* 145, 874–884 e875 (2013).
16. Klein, S. et al. Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AEV0991 in Liver Cirrhosis. *PloS one* 10, e0138732 (2015).
17. Karcigolu, S. S. et al. The Role of RAAS Inhibition by Aliskiren on Paracetamol-Induced Hepatotoxicity Model in Rats. *J Cell Biochem* 117, 638–646 (2016).
18. Lee, K. C. et al. Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet. *PloS one* 8, e77817 (2013).
19. Aihara, Y. et al. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. *Hepatology research: the official journal of the Japan Society of Hepatology* 43, 1241–1250 (2013).
20. Hsieh, Y. C. et al. Aliskiren reduces portal pressure and intrahepatic resistance in bilary cirrhotic rats. *J Chin Med Assoc* 75, 501–508 (2012).
21. Chang, C. C. et al. Aliskiren reduces portal pressure in portal hypertensive rats. *European journal of clinical investigation* 42, 526–533 (2012).
22. Lee, K. C. et al. Aliskiren attenuates chronic carbon tetrachloride-induced liver injury in mice. *European journal of clinical investigation* 42, 1261–1271 (2012).
23. Schepeke, M. et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. *Gastroenterology* 121, 389–395 (2001).
24. Schepeke, M. et al. Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study. *The American journal of gastroenterology* 103, 1152–1158 (2008).
25. Fernandez-Esparrach, G. et al. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. *Journal of hepatology* 26, 614–620 (1997).
26. Werneke, H., Spech, H. J. & Muller, G. Studies on the activity of the renin-angiotensin-aldosterone system (RAAS) in patients with cirrhosis of the liver. *Klinische Wochenschrift* 56, 389–397 (1978).
27. Goh, G. B. et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. *Liver international: official journal of the International Association for the Study of the Liver* 35, 979–985 (2015).
28. Pelusi, S. et al. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. *PloS one* **11**, e0163069 (2016).

29. Pasarin, M. et al. Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. *PloS one* **7**, e32785 (2012).

30. Francque, S. et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. *Laboratory investigation; a journal of technical methods and pathology* **92**, 1428–1439 (2012).

31. Van der Graaff, D. et al. Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. *Laboratory investigation; a journal of technical methods and pathology*, https://doi.org/10.1038/s41374-017-0018-z (2018).

32. de Franchis, R. & Faculty, B. V. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *Journal of hepatology* **63**, 743–752 (2015).

33. Wang, D. et al. Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats. *Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*, https://doi.org/10.1016/j.dld.2014.12.017 (2015).

34. Klein, S., Schierwagen, R., Uschner, F. E. & Trebicka, J. Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension. *Methods Mol Biol* **1627**, 91–116 (2017).

35. Trebicka, J. et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. *Journal of hepatology* **53**, 702–712 (2010).

**Acknowledgements**

The authors thank Gudrun Hack and Silke Bellinghausen for excellent technical assistance, as well as Sabine Dentler for English proof-reading.

**Author Contributions**

S.K., C.E.K., J.T. wrote the first draft of the article and acquired, analyzed and interpreted the data. S.K., M.G., S.G., M.H., K.K., R.S., F.E.U., F.M., M.E.N. acquired, analyzed and interpreted the data. S.K., C.E.K., A.P., M.G., S.G., M.H., K.K., R.S., G.K., T.W., M.B., T.S. provided substantial material and methods and interpreted data. S.K., T.S., J.T. designed the original study, interpreted data, supervised the study and obtained financial support for the study. All authors reviewed the draft for important intellectual content and approved the final article for submission.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-019-48024-4.

**Competing Interests:** This study was supported by grants from the Deutsche Forschungsgemeinschaft (SFB TRR57 P18), Cellex Foundation (PREDICT), European Union’s Horizon 2020 Research and Innovation Programme (No. 668031) and Societal Challenges - Health, Demographic Change and Wellbeing (No. 731875). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019